Autres langues Syndax Pharmaceuticals, Inc.

Actions

SNDX

US87164F1057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
21,06 ^USD	+2,38%		+1,25%	-2,55%

08/04	Syndax Pharmaceuticals, Inc. Présente des données pédiatriques positives de l'étude pivot AUGMENT-101 sur Revumenib dans la leucémie aiguë KMT2Ar récidivante/réfractaire lors de la séance plénière de l'ASPHO	CI
28/03	Syndax Pharmaceuticals, Inc. Annonce de la fin du recrutement de la cohorte de l'essai pivot AUGMENT-101 de patients atteints de leucémie myéloïde aiguë mNPM1 en rechute/réfractaire	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27/03
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26/03
Syndax Says Revumenib NDA Granted FDA Priority Review	26/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	26/03
Sector Update: Health Care Stocks Rise Monday Afternoon	18/03
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18/03
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer	18/03
Syndax Pharmaceuticals, Inc. Announces Executive Changes	18/03
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	01/03
Syndax: Q4 Earnings Snapshot	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Syndax Announces Participation at Two Upcoming Investor Conferences	26/02
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024	20/02
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Syndax Pharmaceuticals, Inc.

Actions

SNDX

US87164F1057

Autres langues

Filtres